Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Leukemia, Myeloid, Chronic-Phase 6Neoplasm Metastasis 4Neoplasms 3Philadelphia Chromosome 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Leukemia 2Synovitis, Pigmented Villonodular 1Sarcoma 1Recurrence 1Peritoneal Neoplasms 1Neoplasm, Residual 1Melanoma 1Leukemia, Myeloid 1Hematologic Diseases 1Giant Cell Tumor of Tendon Sheath 1Genital Neoplasms, Female 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Chordoma 1Cholangiocarcinoma 1Breast Neoplasms 1Blast Crisis 1Appendiceal Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

nilotinib 2asciminib 2Dasatinib 2Cyclophosphamide 2fludarabine 1bosutinib 1Vincristine 1Prednisone 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Imatinib Mesylate 1Etoposide 1Dexamethasone 1Daunorubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Philadelphia Chromosome × nilotinib × 1 year × Clear all
NCT04971226 2026-06-05

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Novartis

Phase 3 Active not recruiting
405 enrolled 18 charts 1 FDA
MyeloidOther hematologic neoplasm

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡